| |
N
|
BCAT1
|
IKZF1
|
IRF4
|
|---|
|
n, Posa (%, 95% CI)
|
OR (95% CI)b
|
n, Pos. (%, 95% CI)
|
OR (95% CI)
|
n, Pos. (%, 95% CI)
|
OR (95% CI)
|
|---|
|
All cases
|
1620
|
173 (10.7, 9–12)
|
–
|
185 (11.4, 10–13)
|
–
|
138 (8.5, 7–9)
|
–
|
|
Cancer
|
184
|
87 (47.3, 40–55)
|
15.8 (10–24)*
|
109 (59.2, 52–66)
|
32.6 (21–51)*
|
92 (50.0, 43–57)
|
44.6 (26–77)*
|
|
Early stage
|
98
|
38 (38.8, 29–49)
|
11.2 (7–19)*
|
51 (52.0, 42–62)
|
24.3 (15–41)*
|
40 (40.8, 31–51)
|
30.7 (17–56)*
|
|
Late stage
|
84
|
48 (57.1, 46–68)
|
23.5 (14–40)*
|
56 (66.7, 56–77)
|
44.9 (26–80)*
|
50 (59.5, 48–70)
|
65.5 (35–124)*
|
|
Stage I
|
41
|
8 (19.5, 10–34)
|
4.3 (2–10)*
|
11 (26.8, 13–41)
|
8.2 (4–18)*
|
7 (17.1, 5–29)
|
9.2 (4–23)*
|
|
Stage II
|
57
|
30 (52.6, 40–65)
|
19.6 (11–35)*
|
40 (70.2, 58–82)
|
52.8 (27–99)*
|
33 (57.9, 45–71)
|
61.3 (30–122)*
|
|
Stage III
|
51
|
23 (45.1, 33–59)
|
14.5 (8–27)*
|
33 (64.7, 51–78)
|
41.1 (21–81)*
|
28 (54.9, 41–69)
|
54.2 (27–112)*
|
|
Stage IV
|
33
|
25 (75.8, 59–87)
|
55.1 (24–121)*
|
23 (69.7, 53–86)
|
51.6 (23–114)*
|
22 (66.7, 50–84)
|
89.1 (36–209)*
|
|
Unstaged
|
2
|
1 (50.0, 3.–97)
|
17.6 (91–335)
| |
–*
|
2 (100, 16–100)
|
–*
|
|
Adenoma
|
616
|
42 (6.8, 5–9)
|
1.3 (1–2)
|
41 (6.7, 5–9)
|
1.6 (1–3)
|
28 (4.5, 3–6)
|
2.1 (1–4)*
|
|
Advanced
|
337
|
29 (8.6, 6–12)
|
1.7 (1–3)*
|
29 (8.6, 6–12)
|
1.7 (1–3)*
|
20 (5.9, 3–9)
|
2.8 (2–5)*
|
|
Non-advanced
|
279
|
13 (4.7, 3–8)
|
0.7 (0.5–2)
|
12 (4.3, 2–7)
|
1.0 (0.5–2)
|
8 (2.9, 1–5)
|
1.3 (0.6–3)
|
|
HGDc
|
35
|
5 (14.3, 6–30)
|
2.9 (1–8)*
|
6 (17.1, 8–33)
|
4.6 (2–12)*
|
7 (20.0, 10–36)
|
11.1 (4–29)*
|
|
LGDc
|
549
|
35 (6.4, 5–9)
|
1.2 (0.7–1.9)
|
32 (5.8, 4–8)
|
1.4 (1–2)
|
18 (3.3, 2–5)
|
1.5 (0.8–3)
|
|
No Neoplasia
|
820
|
44 (5.4, 4–7)
|
Ref
|
35 (4.3, 3–6)
|
Ref
|
18 (2.2, 1–3)
|
Ref
|
|
Non-neoplastic pathologiesd
|
252
|
14 (5.6, 3–8)
|
–
|
9 (3.6, 1–6)
|
–
|
10 (4.0, 2–6)
|
–
|
|
Healthy colon
|
568
|
30 (5.3, 3–7)
|
–
|
26 (4.6, 3–6)
|
–
|
8 (1.4, 0.4–2)
|
–
|
- aAt least one PCR replicate positive for DNA methylation
- bOdds ratio (95% CI) compared to cases without neoplasia (Ref), *p values < 0.05
- cThe severity of dysplasia was available for 584 of 616 adenomas; HGD, high grade dysplasia; LGD, low grade dysplasia
- dBenign polyps (hyperplastic, unspecified, inflammatory, other polyps), inflammatory bowel disease, diverticular disease, angiodysplasia, hemorrhoids
